<abstract xmlns="http://www.w3.org/1999/xhtml"><p> Here we present the concept of making own patient’s anti-cancer treatment more efficient and starting at testing the efficacy of immunological system. The respective tests are suggested, with special attention devoted to tumour-induced microenvironmental changes. The tumour should be considered to represent a complex tissue in which the cancer cells communicate directly and indirectly with the surrounding cellular immunological surrounding and develope traits that promote their own survival. The results of tests allow to propose a rational, individually profiled treatment of a patient, especially directed to elimination of blocks inhibiting the immunological system due to effects of cancer cells. The elimination can be implemented using commercially available antibodies, targeted at the cell surface receptors for inhibitors of T lymphocytes (CTLA-4 and PD-1). Outcome of the therapy is slow to appear and the results used to be selective. Some patients gain long term improvement and respective predictive markers are now tested. It is assumed that the future anti-cancer therapy will be individually targeted, based on individual tests and an assistance of own immunological system of the cancer patient.</p></abstract>

Here we present the concept of making own patient’s anti-cancer treatment more efficient and starting at testing the efficacy of immunological system. The respective tests are suggested, with special attention devoted to tumour-induced microenvironmental changes. The tumour should be considered to represent a complex tissue in which the cancer cells communicate directly and indirectly with the surrounding cellular immunological surrounding and develope traits that promote their own survival. The results of tests allow to propose a rational, individually profiled treatment of a patient, especially directed to elimination of blocks inhibiting the immunological system due to effects of cancer cells. The elimination can be implemented using commercially available antibodies, targeted at the cell surface receptors for inhibitors of T lymphocytes (CTLA-4 and PD-1). Outcome of the therapy is slow to appear and the results used to be selective. Some patients gain long term improvement and respective predictive markers are now tested. It is assumed that the future anti-cancer therapy will be individually targeted, based on individual tests and an assistance of own immunological system of the cancer patient.

Problems of Cancer Treatment. Part 2. Treatment Based on Modification of Anticancer Immunological Responses in Therapy

M.Nałęcz Institute of Biocybernetcics and Biomedical Engineering, PAN, Warsaw,

Laboratory of Cytometry, Medical Centre for Postgraduate Education, Warsaw,

Chair and Department of Internal Diseases, Pneumonology and Allergology, Warsaw Medical University,

Medical Journal of Cell Biology

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.

Here we present the concept of making own patient’s anti-cancer treatment more efficient and starting at testing the efficacy of immunological system. The...

Problems of Cancer Treatment. Part 2. Treatment Based on Modification of Anticancer Immunological Responses in Therapy

Publié en ligne: 26 avr. 2017

Pages: 96 - 112

DOI: https://doi.org/10.1515/acb-2017-0007

Mots clés
immunotherapy, PD-1, CTLA-4

© by Jerzy Kawiak

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.

Problems of Cancer Treatment. Part 2. Treatment Based on Modification of Anticancer Immunological Responses in Therapy

Publié en ligne: 26 avr. 2017

Pages: 96 - 112

DOI: https://doi.org/10.1515/acb-2017-0007

Mots clésimmunotherapy, PD-1, CTLA-4

© by Jerzy Kawiak

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.

Mots clés
immunotherapy, PD-1, CTLA-4